title: Assessment of anterior chamber inflammation after intravitreal bevacizumab injection in different ocular exudative diseases.
abstract: OBJECTIVE
  To investigate the inflammation of the anterior chamber after intravitreal bevacizumab injection in different ocular exudative diseases.
  
  
  METHODS
  The study included 76 eyes from 62 consecutive patients with different ocular exudative diseases. The patients were divided into the 3 following groups: group 1 (nonproliferative diabetic retinopathy), group 2 (choroidal neovascularization secondary to age-related macular degeneration), and group 3 (macular edema with branch or central retinal vein occlusion). The study also included 32 age-matched control patients. Inflammation of the anterior chamber was examined with flare-cell photometry before and after an intravitreal injection of 1.25 mg of bevacizumab.
  
  
  RESULTS
  There were no statistically significant differences between the measurements at baseline and postoperative day 1, 3, 7, or 30 in any of the groups (p>0.05).
  
  
  CONCLUSIONS
  The extent of inflammation in the anterior chamber did not change after intravitreal bevacizumab injection in patients with nonproliferative diabetic retinopathy, choroidal neovascularization secondary to age-related macular degeneration, or macular edema due to branch or central vein occlusion.
authors.affiliation: Istanbul University, Istanbul Faculty of Medicine, Department of Ophthalmology, Istanbul, Turkey. byeniad@yahoo.com
authors.forename: Baris
authors.initials: B
authors.lastname: Yeniad
authors.forename: Ozen
authors.initials: O
authors.lastname: Ayranci
authors.forename: Samuray
authors.initials: S
authors.lastname: Tuncer
authors.forename: Nur
authors.initials: N
authors.lastname: Kir
authors.forename: Tunc
authors.initials: T
authors.lastname: Ovali
authors.forename: Ilknur
authors.initials: I
authors.lastname: Tugal-Tutkun
authors.forename: Koray
authors.initials: K
authors.lastname: Akarcay
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000867:Anterior Chamber / Q000187:drug effects / Q000473:pathology*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy; D005122:Exudates and Transudates; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D007500:Iritis / Q000139:chemically induced / Q000175:diagnosis* / Q000188:drug therapy; D007834:Lasers; D008268:Macular Degeneration / Q000188:drug therapy; D008269:Macular Edema / Q000188:drug therapy; D008297:Male; D010783:Photometry; D012164:Retinal Diseases / Q000188:drug therapy*; D012170:Retinal Vein Occlusion / Q000188:drug therapy; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab